PeriCor Therapeutics has announced positive preclinical results for cardioprotective agent, GP531, at the European Heart Failure Congress 2009 in Nice, France. The study was funded by PeriCor and
Novartis has announced that the investigational biological therapy Ilaris produced rapid and sustained remission of symptoms in patients with a rare and potentially life-threatening auto-inflammatory disease, cryopyrin-associated periodic
Affymax has announced that the independent Data Monitoring Committee (DMC), which provides oversight for the Phase-III program for Hematid, has completed another review. DMC has informed the company
Cerus, and a subsidiary of Grifols have announced that the two companies have entered into an agreement to collaborate on the development of red blood cell treatment sets
Marc Oczachowski, EDAP’s chief executive officer, stated that the company strongly believes Jorge Litter in Argentina, H. Strattner in Brazil and UMS in Chile are the right partners
PolyMedix has received a research contract worth $1.6 million from the Defense Threat Reduction Agency (DTRA), to develop new defensin-mimetic antibiotic compounds. The primary goal of the contract
Pfizer has discontinued the SUN 1094 phase III trial of Sutent (sunitinib malate) plus paclitaxel vs. bevacizumab plus paclitaxel, for the first line treatment of patients with advanced
Pfizer has announced the launch of Toviaz (fesoterodine fumarate), an extended release tablets and YourWay plan, a customizable support plan for overactive bladder patients, which are now available
Arbor, a specialty pharmaceutical company, has announced the launch of Zinotic ES as a new treatment option for Acute Otitis Externa (AOE). Zinotic ES is an extra strength
Bayer HealthCare and Genzyme have received regulatory approvals for the strategic alliance announced on March 31, 2009. With the approval, the legal closing of the transaction is now
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.